Marked Long‐Term Improvement in Lung Function in Melanoma Differentiation–Associated Protein 5 Antibody–Positive Dermatomyositis Patients: Experience of a Single‐Center Longitudinal Cohort in North America
Arthritis Care & Research · 2026
DOI: 10.1002/acr.80004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Jenice X Cheah und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles. Hauptthemen laut MEDLINE: Interferon-Induced Helicase, IFIH1, Dermatomyositis, Lung Diseases, Interstitial, Autoantibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Objective
The objective of this study was to describe the longitudinal disease course and pulmonary outcomes of North American patients with melanoma differentiation–associated protein 5 (MDA5) antibody–associated dermatomyositis (DM).
Methods
Thirty patients with MDA5 antibody–associated DM were identified in a single‐center longitudinal cohort of 352 patients with idiopathic inflammatory myopathies. Longitudinal assessments of patient clinical and laboratory disease characteristics, pulmonary function tests (PFT), and high‐resolution computed tomography chest scans were conducted.
Results
Eighty percent (n = 24/30) of patients with MDA5 antibody–associated DM had interstitial lung disease (ILD). The overall mortality was low (2/24 at a mean ± SD follow‐up of 4.0 ± 0.8 years). At this follow‐up, patients were receiving 3.1 ± 1.3 therapies, including 79% receiving intravenous Ig (IVIg), 58% receiving rituximab, 67% receiving mycophenolate, and 63% receiving glucocorticoids. In 18 of 22 surviving patients with ILD who had two‐year longitudinal follow‐up available at 1.8 ± 0.6 years, improvements of 16% and 17% predicted forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DL co ) were noted. In 10 of 18 patients with additional long‐term follow‐up available (mean ± SD 6.8 ± 3.4 years), improvements of 24% and 20% predicted FVC and DL co were noted. MDA5 antibody and interleukin‐15 (IL‐15) levels and paraoxonase 1 (PON1) enzyme activity correlated significantly with disease activity at baseline and longitudinally.
Conclusion
In a North American MDA5 antibody–associated DM‐ILD cohort treated with aggressive combination immunomodulatory therapy including predominantly mycophenolate, IVIg, and rituximab, disease mortality was low and lung function improved markedly. IL‐15, PON1, and MDA5 antibody titers warrant further investigation as disease activity biomarkers in this high‐risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California, Los Angeles.
ORCID-Profile: Sangmee S Bae
Förderung
- NIAMS NIH HHS
Zitieren
APA
Cheah, J. X., Bae, S. S., De Leon, T., Lee, Y., Guo, R., Elashoff, D., Wang, J., Shahbazian, A., & Charles-Schoeman, C. (2026). Marked Long‐Term Improvement in Lung Function in Melanoma Differentiation–Associated Protein 5 Antibody–Positive Dermatomyositis Patients: Experience of a Single‐Center Longitudinal Cohort in North America. Arthritis Care & Research. https://doi.org/10.1002/acr.80004
Vancouver
Cheah JX, Bae SS, De Leon T, Lee Y, Guo R, Elashoff D, et al. Marked Long‐Term Improvement in Lung Function in Melanoma Differentiation–Associated Protein 5 Antibody–Positive Dermatomyositis Patients: Experience of a Single‐Center Longitudinal Cohort in North America. Arthritis Care & Research. 2026. doi:10.1002/acr.80004
BibTeX
@article{Cheah2026,
author = {Cheah, Jenice X and Bae, Sangmee S and De Leon, Tiffany and Lee, Yuna and Guo, Rong and Elashoff, David and Wang, Jennifer and Shahbazian, Ani and Charles-Schoeman, Christina},
title = {Marked Long‐Term Improvement in Lung Function in Melanoma Differentiation–Associated Protein 5 Antibody–Positive Dermatomyositis Patients: Experience of a Single‐Center Longitudinal Cohort in North America},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.80004}
}
EUVIMED